A panelist outlines how advances in molecular diagnostics, particularly NGS, are refining follicular lymphoma classification and informing selective therapeutic decisions—most notably the use of EZH2-targeted therapy. He describes how emerging agents such as CD19-directed therapies, bispecific antibodies, and potent new combinations are reshaping treatment sequencing, which must also account for antigen preservation, prior response durability, and individual patient factors. Together, these updates reflect a rapidly evolving landscape that demands personalized, forward-thinking treatment planning.
